FDA Approves Vanda Pharmaceuticals' BYSANTI for Schizophrenia and Bipolar I

Key Facts

1The U.S. FDA approved BYSANTI (milsaperidone) as a first-line therapy for manic or mixed episodes associated with bipolar I disorder and for schizophrenia in adults.

2BYSANTI is a New Chemical Entity (NCE) that belongs to the class of atypical antipsychotics.

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that the U.S. Food and Drug Administration (FDA) has approved its new drug, BYSANTI (milsaperidone). The medication is authorized as a first-line treatment for adults suffering from schizophrenia and manic or mixed episodes associated with bipolar I disorder. BYSANTI is classified as a New Chemical Entity (NCE) and belongs to the class of atypical antipsychotics. This regulatory milestone marks a significant expansion of Vanda's psychiatric portfolio, offering a new therapeutic option for complex mental health conditions. Market analysts view this approval as a major catalyst for the company's long-term revenue growth and stock performance. The successful review underscores the drug's safety and efficacy profile as established in clinical trials.